130 related articles for article (PubMed ID: 31635489)
21. Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.
Rutten KHG; Raymakers RAP; Hazenberg BPC; Nienhuis HLA; Vellenga E; Minnema MC
Amyloid; 2018 Dec; 25(4):227-233. PubMed ID: 30513220
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.
Shen KN; Zhang CL; Tian Z; Feng J; Wang YN; Sun J; Zhang L; Cao XX; Zhou DB; Li J
Amyloid; 2019 Jun; 26(2):66-73. PubMed ID: 31074308
[No Abstract] [Full Text] [Related]
24. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
25. Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.
Chen EC; Rubinstein S; Soto C; Bombardi RG; Day SB; Myers L; Zaytsev A; Majedi M; Cornell RF; Crowe JE
PLoS One; 2020; 15(7):e0235713. PubMed ID: 32634163
[TBL] [Abstract][Full Text] [Related]
26. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis.
Hammons L; Brazauskas R; Pasquini M; Hamadani M; Hari P; D'Souza A
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):105-111. PubMed ID: 28830801
[TBL] [Abstract][Full Text] [Related]
27. Multiorgan involvement by amyloid light chain amyloidosis.
Li G; Han D; Wei S; Wang H; Chen L
J Int Med Res; 2019 Apr; 47(4):1778-1786. PubMed ID: 30803274
[TBL] [Abstract][Full Text] [Related]
28. Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis.
Lentzsch S; Lagos GG; Comenzo RL; Zonder JA; Pregja S; Osman K; Tsai WY; Landau H; Sanchorawala V
Amyloid; 2019; 26(sup1):113-114. PubMed ID: 31343313
[No Abstract] [Full Text] [Related]
29. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
30. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.
Paiva B; Martinez-Lopez J; Corchete LA; Sanchez-Vega B; Rapado I; Puig N; Barrio S; Sanchez ML; Alignani D; Lasa M; García de Coca A; Pardal E; Oriol A; Garcia ME; Escalante F; González-López TJ; Palomera L; Alonso J; Prosper F; Orfao A; Vidriales MB; Mateos MV; Lahuerta JJ; Gutierrez NC; San Miguel JF
Blood; 2016 Jun; 127(24):3035-9. PubMed ID: 27069257
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients.
Hasserjian RP; Goodman HJ; Lachmann HJ; Muzikansky A; Hawkins PN
Histopathology; 2007 Apr; 50(5):567-73. PubMed ID: 17394492
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
33. Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma.
Schreiner S; Berghaus N; Poos AM; Raab MS; Besemer B; Fenk R; Goldschmidt H; Mai EK; Müller-Tidow C; Weinhold N; Hegenbart U; Huhn S; Schönland SO
Amyloid; 2024 Jun; 31(2):86-94. PubMed ID: 38206120
[TBL] [Abstract][Full Text] [Related]
34. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Scheffler M; Ihle MA; Hein R; Merkelbach-Bruse S; Scheel AH; Siemanowski J; Brägelmann J; Kron A; Abedpour N; Ueckeroth F; Schüller M; Koleczko S; Michels S; Fassunke J; Pasternack H; Heydt C; Serke M; Fischer R; Schulte W; Gerigk U; Nogova L; Ko YD; Abdulla DSY; Riedel R; Kambartel KO; Lorenz J; Sauerland I; Randerath W; Kaminsky B; Hagmeyer L; Grohé C; Eisert A; Frank R; Gogl L; Schaepers C; Holzem A; Hellmich M; Thomas RK; Peifer M; Sos ML; Büttner R; Wolf J
J Thorac Oncol; 2019 Apr; 14(4):606-616. PubMed ID: 30605727
[TBL] [Abstract][Full Text] [Related]
35. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
Bhutani D; Leng S; Lentzsch S
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
[TBL] [Abstract][Full Text] [Related]
36. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
37. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
38. AL amyloidosis: from molecular mechanisms to targeted therapies.
Merlini G
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):1-12. PubMed ID: 29222231
[TBL] [Abstract][Full Text] [Related]
39. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
40. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
